['rheumatoid arthritis']
['gdc-0853', 'adalimumab', 'folic acid', 'mtx', 'placebo']

        Inclusion Criteria:

          -  Have a diagnosis of adult-onset RA as defined by the 2010 American College of
             Rheumatology/European League Against Rheumatism Classification Criteria for RA

          -  RA disease activity by joint counts and laboratory markers of inflammation: greater
             than or equal to (>=) 6 tender/painful joints on motion (68 joint count) and >= 6
             swollen joints (66 joint count) at both screening and Day 1 (randomization)

          -  For MTX-inadequate response (IR) participants: must have had an inadequate response to
             MTX

          -  For TNF-IR participants: must have had an inadequate response or intolerance to
             previous treatment with at least 1 and no more than 2 biologic TNF-alpha inhibitors
             and may have also been exposed to no more than one biologic non-TNF-alpha inhibitor

          -  High sensitivity C-reactive protein of >= 0.400 milligrams per deciliter (mg/dL) for
             Cohort 1 and >= 0.650 mg/dL for Cohort 2 at screening

        Exclusion Criteria:

          -  History of or current inflammatory joint disease other than RA or other systemic
             autoimmune disorder

          -  For MTX-IR participants: History of treatment with any TNF inhibitor, including
             biosimilar equivalents and history of treatment with biologic non-TNF-alpha inhibitor
             for RA

          -  For all participants: Previous treatment with cell-depleting therapy including B
             cell-depleting therapy (e.g., anti-cluster of differentiation 20-directed therapy such
             as rituximab), tofacitinib, or other Janus kinase inhibitor(s), or alkylating agents

          -  Current treatment with medications that are well known to prolong the QT interval at
             doses that have a clinically meaningful effect on QT

          -  History of non-gallstone-related pancreatitis or chronic pancreatitis

          -  Evidence of serious uncontrolled concomitant cardiac, neurologic, pulmonary, renal,
             hepatic, endocrine, metabolic, or gastrointestinal disease

          -  Evidence of chronic and/or active hepatitis B or C

          -  Women who are pregnant, nursing (breast feeding), or intending to become pregnant
             during the study or within 60 days after completion of the study
      